Pacific Biosciences (PACB) saw its stock soar 8.04% on Tuesday's trading session, driven by positive analyst ratings and price target updates.
Stephens & Co. maintained a $2.50 price target on PACB, expressing confidence in the company's prospects. Meanwhile, Morgan Stanley reiterated a "Hold" rating on the stock, setting a $2.00 price target.
The updates from these analysts reflect optimism surrounding Pacific Biosciences' future performance, boosting investor sentiment and driving the stock's significant upward movement during Tuesday's trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。